Genetic alterations related to BRAF‐FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma
Pilocytic astrocytomas occur rarely in adults and show aggressive tumor behavior. However, their underlying molecular‐genetic events are largely uncharacterized. Hence, 59 adult pilocytic astrocytoma (APA) cases of classical histology were studied (MIB‐1 LI: 1%–5%). Analysis of BRAF alterations usin...
Gespeichert in:
Veröffentlicht in: | Brain pathology (Zurich, Switzerland) Switzerland), 2017-09, Vol.27 (5), p.580-589 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 589 |
---|---|
container_issue | 5 |
container_start_page | 580 |
container_title | Brain pathology (Zurich, Switzerland) |
container_volume | 27 |
creator | Pathak, Pankaj Kumar, Anupam Jha, Prerana Purkait, Suvendu Faruq, Mohammed Suri, Ashish Suri, Vaishali Sharma, Mehar C. Sarkar, Chitra |
description | Pilocytic astrocytomas occur rarely in adults and show aggressive tumor behavior. However, their underlying molecular‐genetic events are largely uncharacterized. Hence, 59 adult pilocytic astrocytoma (APA) cases of classical histology were studied (MIB‐1 LI: 1%–5%). Analysis of BRAF alterations using qRT‐PCR, confirmed KIAA1549‐BRAF fusion in 11 (19%) and BRAF‐gain in 2 (3.4%) cases. BRAF‐V600E mutation was noted in 1 (1.7%) case by sequencing. FGFR1‐mutation and FGFR‐TKD duplication were seen in 7/59 (11.9%) and 3/59 (5%) cases, respectively. Overall 36% of APAs harbored BRAF and/or FGFR genetic alterations. Notably, FGFR related genetic alterations were enriched in tumors of supratentorial region (8/25, 32%) as compared with other locations (P = 0.01). The difference in age of cases with FGFR1‐mutation (Mean age ± SD: 37.2 ± 15 years) vs. KIAA1549‐BRAF fusion (Mean age ± SD: 25.1 ± 4.1 years) was statistically significant (P = 0.03). Combined BRAF and FGFR alterations were identified in 3 (5%) cases. Notably, the cases with more than one genetic alteration were in higher age group (Mean age ± SD: 50 ± 12 years) as compared with cases with single genetic alteration (Mean age ± SD: 29 ± 10; P = 0.003). Immunopositivity of p‐MAPK/p‐MEK1 was found in all the cases examined. The pS6‐immunoreactivity, a marker of mTOR activation was observed in 34/39 (87%) cases. Interestingly, cases with BRAF and/or FGFR related alteration showed significantly lower pS6‐immunostatining (3/12; 25%) as compared with those with wild‐type BRAF and/or FGFR (16/27; 59%) (P = 0.04). Further, analysis of seven IDH wild‐type adult diffuse astrocytomas (DA) showed FGFR related genetic alterations in 43% cases. These and previous results suggest that APAs are genetically similar to IDH wild‐type adult DAs. APAs harbor infrequent BRAF alterations but more frequent FGFR alterations as compared with pediatric cases. KIAA1549‐BRAF fusion inversely correlates with increasing age whereas FGFR1‐mutation associates with older age. Activation of MAPK/ERK/mTOR signaling appears to be an important oncogenic event in APAs and may be underlying event of aggressive tumor behavior. The findings provided a rationale for potential therapeutic advantage of targeting MAPK/ERK/mTOR pathway in APAs. |
doi_str_mv | 10.1111/bpa.12444 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8029314</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1856592673</sourcerecordid><originalsourceid>FETCH-LOGICAL-j4354-fdc6b2e9cc805992a55dfd8c3f807f04fdf45f0a7cb6ce3f187da205ff592db73</originalsourceid><addsrcrecordid>eNpdkc1u1DAUhSMEoqVlwQsgS2y6Sce_SbxBmladAbVVq1G7thz_BI8cZ7ATYHY8As_Ik-DOlKpwN_dI99O5V_cUxTsET1GuWbuRpwhTSl8Uh6hmsCQV4S-zhoiVFYHsoHiT0hpCxCvOXhcHuK5gQxE7LH4sTTCjU0D60UQ5uiEkEI2Xo9FgHMDZar74_fPXYrlYgS6jCciggd6maLppT13Pby9nF6vLWX93swLJdUF6FzrgApB68iPYOD-o7W5JGuODHHp5XLyy0ifz9rEfFfeLi7vzT-XVzfLz-fyqXFPCaGm1qlpsuFINZJxjyZi2ulHENrC2kFptKbNQ1qqtlCEWNbWWGDJrGce6rclR8XHvu5na3mhlwhilF5voehm3YpBO_DsJ7ovohm-igZgTRLPByaNBHL5OJo2id0kZ72Uww5QEaliVd1U1yeiH_9D1MMX8jkxx3OCaVnWTqffPL3o65W8oGZjtge_Om-3THEHxkLbIaYtd2uLsdr4T5A_jrZ7M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1928274678</pqid></control><display><type>article</type><title>Genetic alterations related to BRAF‐FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Pathak, Pankaj ; Kumar, Anupam ; Jha, Prerana ; Purkait, Suvendu ; Faruq, Mohammed ; Suri, Ashish ; Suri, Vaishali ; Sharma, Mehar C. ; Sarkar, Chitra</creator><creatorcontrib>Pathak, Pankaj ; Kumar, Anupam ; Jha, Prerana ; Purkait, Suvendu ; Faruq, Mohammed ; Suri, Ashish ; Suri, Vaishali ; Sharma, Mehar C. ; Sarkar, Chitra</creatorcontrib><description>Pilocytic astrocytomas occur rarely in adults and show aggressive tumor behavior. However, their underlying molecular‐genetic events are largely uncharacterized. Hence, 59 adult pilocytic astrocytoma (APA) cases of classical histology were studied (MIB‐1 LI: 1%–5%). Analysis of BRAF alterations using qRT‐PCR, confirmed KIAA1549‐BRAF fusion in 11 (19%) and BRAF‐gain in 2 (3.4%) cases. BRAF‐V600E mutation was noted in 1 (1.7%) case by sequencing. FGFR1‐mutation and FGFR‐TKD duplication were seen in 7/59 (11.9%) and 3/59 (5%) cases, respectively. Overall 36% of APAs harbored BRAF and/or FGFR genetic alterations. Notably, FGFR related genetic alterations were enriched in tumors of supratentorial region (8/25, 32%) as compared with other locations (P = 0.01). The difference in age of cases with FGFR1‐mutation (Mean age ± SD: 37.2 ± 15 years) vs. KIAA1549‐BRAF fusion (Mean age ± SD: 25.1 ± 4.1 years) was statistically significant (P = 0.03). Combined BRAF and FGFR alterations were identified in 3 (5%) cases. Notably, the cases with more than one genetic alteration were in higher age group (Mean age ± SD: 50 ± 12 years) as compared with cases with single genetic alteration (Mean age ± SD: 29 ± 10; P = 0.003). Immunopositivity of p‐MAPK/p‐MEK1 was found in all the cases examined. The pS6‐immunoreactivity, a marker of mTOR activation was observed in 34/39 (87%) cases. Interestingly, cases with BRAF and/or FGFR related alteration showed significantly lower pS6‐immunostatining (3/12; 25%) as compared with those with wild‐type BRAF and/or FGFR (16/27; 59%) (P = 0.04). Further, analysis of seven IDH wild‐type adult diffuse astrocytomas (DA) showed FGFR related genetic alterations in 43% cases. These and previous results suggest that APAs are genetically similar to IDH wild‐type adult DAs. APAs harbor infrequent BRAF alterations but more frequent FGFR alterations as compared with pediatric cases. KIAA1549‐BRAF fusion inversely correlates with increasing age whereas FGFR1‐mutation associates with older age. Activation of MAPK/ERK/mTOR signaling appears to be an important oncogenic event in APAs and may be underlying event of aggressive tumor behavior. The findings provided a rationale for potential therapeutic advantage of targeting MAPK/ERK/mTOR pathway in APAs.</description><identifier>ISSN: 1015-6305</identifier><identifier>EISSN: 1750-3639</identifier><identifier>DOI: 10.1111/bpa.12444</identifier><identifier>PMID: 27608415</identifier><language>eng</language><publisher>Switzerland: John Wiley & Sons, Inc</publisher><subject>2-Methylisoborneol ; Activation ; Adult ; adult pilocytic astrocytoma ; Adults ; Age ; Age Factors ; Astrocytoma ; Astrocytoma - genetics ; Astrocytoma - metabolism ; Astrocytoma - pathology ; BRAF ; Extracellular signal-regulated kinase ; Female ; FGFR1 ; Fibroblast growth factor receptor 1 ; Fibroblast growth factor receptors ; Histology ; Humans ; Immunoreactivity ; low grade glioma ; Male ; MAP kinase ; MAP Kinase Signaling System ; MAPK/ERK ; Middle Aged ; mTOR ; Mutation ; Polymerase chain reaction ; Proto-Oncogene Proteins B-raf - genetics ; Receptor, Fibroblast Growth Factor, Type 1 - genetics ; Retrospective Studies ; Signal Transduction ; Statistical analysis ; TOR protein ; TOR Serine-Threonine Kinases - metabolism ; Tumors ; Young Adult</subject><ispartof>Brain pathology (Zurich, Switzerland), 2017-09, Vol.27 (5), p.580-589</ispartof><rights>2017 International Society of Neuropathology</rights><rights>2017 International Society of Neuropathology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029314/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029314/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,27924,27925,45574,45575,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27608415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pathak, Pankaj</creatorcontrib><creatorcontrib>Kumar, Anupam</creatorcontrib><creatorcontrib>Jha, Prerana</creatorcontrib><creatorcontrib>Purkait, Suvendu</creatorcontrib><creatorcontrib>Faruq, Mohammed</creatorcontrib><creatorcontrib>Suri, Ashish</creatorcontrib><creatorcontrib>Suri, Vaishali</creatorcontrib><creatorcontrib>Sharma, Mehar C.</creatorcontrib><creatorcontrib>Sarkar, Chitra</creatorcontrib><title>Genetic alterations related to BRAF‐FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma</title><title>Brain pathology (Zurich, Switzerland)</title><addtitle>Brain Pathol</addtitle><description>Pilocytic astrocytomas occur rarely in adults and show aggressive tumor behavior. However, their underlying molecular‐genetic events are largely uncharacterized. Hence, 59 adult pilocytic astrocytoma (APA) cases of classical histology were studied (MIB‐1 LI: 1%–5%). Analysis of BRAF alterations using qRT‐PCR, confirmed KIAA1549‐BRAF fusion in 11 (19%) and BRAF‐gain in 2 (3.4%) cases. BRAF‐V600E mutation was noted in 1 (1.7%) case by sequencing. FGFR1‐mutation and FGFR‐TKD duplication were seen in 7/59 (11.9%) and 3/59 (5%) cases, respectively. Overall 36% of APAs harbored BRAF and/or FGFR genetic alterations. Notably, FGFR related genetic alterations were enriched in tumors of supratentorial region (8/25, 32%) as compared with other locations (P = 0.01). The difference in age of cases with FGFR1‐mutation (Mean age ± SD: 37.2 ± 15 years) vs. KIAA1549‐BRAF fusion (Mean age ± SD: 25.1 ± 4.1 years) was statistically significant (P = 0.03). Combined BRAF and FGFR alterations were identified in 3 (5%) cases. Notably, the cases with more than one genetic alteration were in higher age group (Mean age ± SD: 50 ± 12 years) as compared with cases with single genetic alteration (Mean age ± SD: 29 ± 10; P = 0.003). Immunopositivity of p‐MAPK/p‐MEK1 was found in all the cases examined. The pS6‐immunoreactivity, a marker of mTOR activation was observed in 34/39 (87%) cases. Interestingly, cases with BRAF and/or FGFR related alteration showed significantly lower pS6‐immunostatining (3/12; 25%) as compared with those with wild‐type BRAF and/or FGFR (16/27; 59%) (P = 0.04). Further, analysis of seven IDH wild‐type adult diffuse astrocytomas (DA) showed FGFR related genetic alterations in 43% cases. These and previous results suggest that APAs are genetically similar to IDH wild‐type adult DAs. APAs harbor infrequent BRAF alterations but more frequent FGFR alterations as compared with pediatric cases. KIAA1549‐BRAF fusion inversely correlates with increasing age whereas FGFR1‐mutation associates with older age. Activation of MAPK/ERK/mTOR signaling appears to be an important oncogenic event in APAs and may be underlying event of aggressive tumor behavior. The findings provided a rationale for potential therapeutic advantage of targeting MAPK/ERK/mTOR pathway in APAs.</description><subject>2-Methylisoborneol</subject><subject>Activation</subject><subject>Adult</subject><subject>adult pilocytic astrocytoma</subject><subject>Adults</subject><subject>Age</subject><subject>Age Factors</subject><subject>Astrocytoma</subject><subject>Astrocytoma - genetics</subject><subject>Astrocytoma - metabolism</subject><subject>Astrocytoma - pathology</subject><subject>BRAF</subject><subject>Extracellular signal-regulated kinase</subject><subject>Female</subject><subject>FGFR1</subject><subject>Fibroblast growth factor receptor 1</subject><subject>Fibroblast growth factor receptors</subject><subject>Histology</subject><subject>Humans</subject><subject>Immunoreactivity</subject><subject>low grade glioma</subject><subject>Male</subject><subject>MAP kinase</subject><subject>MAP Kinase Signaling System</subject><subject>MAPK/ERK</subject><subject>Middle Aged</subject><subject>mTOR</subject><subject>Mutation</subject><subject>Polymerase chain reaction</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Receptor, Fibroblast Growth Factor, Type 1 - genetics</subject><subject>Retrospective Studies</subject><subject>Signal Transduction</subject><subject>Statistical analysis</subject><subject>TOR protein</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>1015-6305</issn><issn>1750-3639</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1u1DAUhSMEoqVlwQsgS2y6Sce_SbxBmladAbVVq1G7thz_BI8cZ7ATYHY8As_Ik-DOlKpwN_dI99O5V_cUxTsET1GuWbuRpwhTSl8Uh6hmsCQV4S-zhoiVFYHsoHiT0hpCxCvOXhcHuK5gQxE7LH4sTTCjU0D60UQ5uiEkEI2Xo9FgHMDZar74_fPXYrlYgS6jCciggd6maLppT13Pby9nF6vLWX93swLJdUF6FzrgApB68iPYOD-o7W5JGuODHHp5XLyy0ifz9rEfFfeLi7vzT-XVzfLz-fyqXFPCaGm1qlpsuFINZJxjyZi2ulHENrC2kFptKbNQ1qqtlCEWNbWWGDJrGce6rclR8XHvu5na3mhlwhilF5voehm3YpBO_DsJ7ovohm-igZgTRLPByaNBHL5OJo2id0kZ72Uww5QEaliVd1U1yeiH_9D1MMX8jkxx3OCaVnWTqffPL3o65W8oGZjtge_Om-3THEHxkLbIaYtd2uLsdr4T5A_jrZ7M</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Pathak, Pankaj</creator><creator>Kumar, Anupam</creator><creator>Jha, Prerana</creator><creator>Purkait, Suvendu</creator><creator>Faruq, Mohammed</creator><creator>Suri, Ashish</creator><creator>Suri, Vaishali</creator><creator>Sharma, Mehar C.</creator><creator>Sarkar, Chitra</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TK</scope><scope>JQ2</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201709</creationdate><title>Genetic alterations related to BRAF‐FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma</title><author>Pathak, Pankaj ; Kumar, Anupam ; Jha, Prerana ; Purkait, Suvendu ; Faruq, Mohammed ; Suri, Ashish ; Suri, Vaishali ; Sharma, Mehar C. ; Sarkar, Chitra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j4354-fdc6b2e9cc805992a55dfd8c3f807f04fdf45f0a7cb6ce3f187da205ff592db73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>2-Methylisoborneol</topic><topic>Activation</topic><topic>Adult</topic><topic>adult pilocytic astrocytoma</topic><topic>Adults</topic><topic>Age</topic><topic>Age Factors</topic><topic>Astrocytoma</topic><topic>Astrocytoma - genetics</topic><topic>Astrocytoma - metabolism</topic><topic>Astrocytoma - pathology</topic><topic>BRAF</topic><topic>Extracellular signal-regulated kinase</topic><topic>Female</topic><topic>FGFR1</topic><topic>Fibroblast growth factor receptor 1</topic><topic>Fibroblast growth factor receptors</topic><topic>Histology</topic><topic>Humans</topic><topic>Immunoreactivity</topic><topic>low grade glioma</topic><topic>Male</topic><topic>MAP kinase</topic><topic>MAP Kinase Signaling System</topic><topic>MAPK/ERK</topic><topic>Middle Aged</topic><topic>mTOR</topic><topic>Mutation</topic><topic>Polymerase chain reaction</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Receptor, Fibroblast Growth Factor, Type 1 - genetics</topic><topic>Retrospective Studies</topic><topic>Signal Transduction</topic><topic>Statistical analysis</topic><topic>TOR protein</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pathak, Pankaj</creatorcontrib><creatorcontrib>Kumar, Anupam</creatorcontrib><creatorcontrib>Jha, Prerana</creatorcontrib><creatorcontrib>Purkait, Suvendu</creatorcontrib><creatorcontrib>Faruq, Mohammed</creatorcontrib><creatorcontrib>Suri, Ashish</creatorcontrib><creatorcontrib>Suri, Vaishali</creatorcontrib><creatorcontrib>Sharma, Mehar C.</creatorcontrib><creatorcontrib>Sarkar, Chitra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Brain pathology (Zurich, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pathak, Pankaj</au><au>Kumar, Anupam</au><au>Jha, Prerana</au><au>Purkait, Suvendu</au><au>Faruq, Mohammed</au><au>Suri, Ashish</au><au>Suri, Vaishali</au><au>Sharma, Mehar C.</au><au>Sarkar, Chitra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic alterations related to BRAF‐FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma</atitle><jtitle>Brain pathology (Zurich, Switzerland)</jtitle><addtitle>Brain Pathol</addtitle><date>2017-09</date><risdate>2017</risdate><volume>27</volume><issue>5</issue><spage>580</spage><epage>589</epage><pages>580-589</pages><issn>1015-6305</issn><eissn>1750-3639</eissn><abstract>Pilocytic astrocytomas occur rarely in adults and show aggressive tumor behavior. However, their underlying molecular‐genetic events are largely uncharacterized. Hence, 59 adult pilocytic astrocytoma (APA) cases of classical histology were studied (MIB‐1 LI: 1%–5%). Analysis of BRAF alterations using qRT‐PCR, confirmed KIAA1549‐BRAF fusion in 11 (19%) and BRAF‐gain in 2 (3.4%) cases. BRAF‐V600E mutation was noted in 1 (1.7%) case by sequencing. FGFR1‐mutation and FGFR‐TKD duplication were seen in 7/59 (11.9%) and 3/59 (5%) cases, respectively. Overall 36% of APAs harbored BRAF and/or FGFR genetic alterations. Notably, FGFR related genetic alterations were enriched in tumors of supratentorial region (8/25, 32%) as compared with other locations (P = 0.01). The difference in age of cases with FGFR1‐mutation (Mean age ± SD: 37.2 ± 15 years) vs. KIAA1549‐BRAF fusion (Mean age ± SD: 25.1 ± 4.1 years) was statistically significant (P = 0.03). Combined BRAF and FGFR alterations were identified in 3 (5%) cases. Notably, the cases with more than one genetic alteration were in higher age group (Mean age ± SD: 50 ± 12 years) as compared with cases with single genetic alteration (Mean age ± SD: 29 ± 10; P = 0.003). Immunopositivity of p‐MAPK/p‐MEK1 was found in all the cases examined. The pS6‐immunoreactivity, a marker of mTOR activation was observed in 34/39 (87%) cases. Interestingly, cases with BRAF and/or FGFR related alteration showed significantly lower pS6‐immunostatining (3/12; 25%) as compared with those with wild‐type BRAF and/or FGFR (16/27; 59%) (P = 0.04). Further, analysis of seven IDH wild‐type adult diffuse astrocytomas (DA) showed FGFR related genetic alterations in 43% cases. These and previous results suggest that APAs are genetically similar to IDH wild‐type adult DAs. APAs harbor infrequent BRAF alterations but more frequent FGFR alterations as compared with pediatric cases. KIAA1549‐BRAF fusion inversely correlates with increasing age whereas FGFR1‐mutation associates with older age. Activation of MAPK/ERK/mTOR signaling appears to be an important oncogenic event in APAs and may be underlying event of aggressive tumor behavior. The findings provided a rationale for potential therapeutic advantage of targeting MAPK/ERK/mTOR pathway in APAs.</abstract><cop>Switzerland</cop><pub>John Wiley & Sons, Inc</pub><pmid>27608415</pmid><doi>10.1111/bpa.12444</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1015-6305 |
ispartof | Brain pathology (Zurich, Switzerland), 2017-09, Vol.27 (5), p.580-589 |
issn | 1015-6305 1750-3639 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8029314 |
source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | 2-Methylisoborneol Activation Adult adult pilocytic astrocytoma Adults Age Age Factors Astrocytoma Astrocytoma - genetics Astrocytoma - metabolism Astrocytoma - pathology BRAF Extracellular signal-regulated kinase Female FGFR1 Fibroblast growth factor receptor 1 Fibroblast growth factor receptors Histology Humans Immunoreactivity low grade glioma Male MAP kinase MAP Kinase Signaling System MAPK/ERK Middle Aged mTOR Mutation Polymerase chain reaction Proto-Oncogene Proteins B-raf - genetics Receptor, Fibroblast Growth Factor, Type 1 - genetics Retrospective Studies Signal Transduction Statistical analysis TOR protein TOR Serine-Threonine Kinases - metabolism Tumors Young Adult |
title | Genetic alterations related to BRAF‐FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A39%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20alterations%20related%20to%20BRAF%E2%80%90FGFR%20genes%20and%20dysregulated%20MAPK/ERK/mTOR%20signaling%20in%20adult%20pilocytic%20astrocytoma&rft.jtitle=Brain%20pathology%20(Zurich,%20Switzerland)&rft.au=Pathak,%20Pankaj&rft.date=2017-09&rft.volume=27&rft.issue=5&rft.spage=580&rft.epage=589&rft.pages=580-589&rft.issn=1015-6305&rft.eissn=1750-3639&rft_id=info:doi/10.1111/bpa.12444&rft_dat=%3Cproquest_pubme%3E1856592673%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1928274678&rft_id=info:pmid/27608415&rfr_iscdi=true |